Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | TACR3 | P29371 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | F9 | P00740 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11080798 | 0.84 | HPGD (0.41) | HPGDALOX5CES2CES1KEAP1 | |
| SCHEMBL2547716 | 0.84 | CES2 (0.47) | HPGDALOX5CES2CES1KEAP1 | |
| SCHEMBL12895886 | 0.83 | HPGD (0.55) | HPGDALOX5CES2CES1KEAP1 | |
| SCHEMBL2370589 | 0.83 | HPGD (0.55) | HPGDALOX5CES2CES1KEAP1 | |
| SCHEMBL9000694 | 0.83 | CES2 (0.56) | HPGDALOX5CES2CES1KEAP1 | |
| SCHEMBL8237520 | 0.83 | HPGD (0.44) | HPGDALOX5CES2CES1KEAP1 | |
| SCHEMBL442866 | 0.82 | CES2 (0.46) | HPGDALOX5CES2CES1KEAP1 | |
| SCHEMBL5084496 | 0.81 | HPGD (0.43) | HPGDALOX5CES2CES1KEAP1 | |
| SCHEMBL2547719 | 0.81 | ALOX5 (0.42) | HPGDALOX5CES2CES1KEAP1 | |
| SCHEMBL202116 | 0.81 | ALOX5 (0.46) | HPGDALOX5CES2CES1KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219485-A1 | FUSED TRICYCLIC DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-08-02 | — | — | EP | disclosed |
| CN-107108562-A | With β2Nitrogen-containing heterocyclic ring derivative with receptor agonistic and M receptor antagonistic activities and application thereof in medicine | 四川海思科制药有限公司 | 2017-08-29 | — | — | CN | disclosed |
| EP-2552912-B1 | SYNTHESIS METHOD FOR PRODUCING TIOTROPIUM BROMIDE | BILGIC MAHMUT (TR) | 2017-08-02 | — | — | EP | disclosed |
| US-7718670-B2 | Quinuclidine amide derivatives | LABORATORIOS ALMIRALL S.A (ES) | 2010-05-18 | — | — | US | disclosed |
| EP-1519933-B1 | QUINUCLIDINE AMIDE DERIVATIVES | ALMIRALL SA (ES) | 2010-05-12 | — | — | EP | disclosed |
| US-7488735-B2 | antagonists of M3 muscarinic receptors; N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-hydroxy-2,2-dithien-2-ylacetamide; respiratory disorders, urological disorders, gastrointestinal disorders, cardiovascular disorders; alkylation | LABORATORIOS ALMIRALL S.A. (ES) | 2009-02-10 | — | — | US | disclosed |
| US-20080234316-A1 | Quinuclidine Amide Derivatives | ALMIRALL AG | 2008-09-25 | — | — | US | disclosed |
| US-20080214600-A1 | Quaternized Quinuclidine Esters | ALMIRALL PRODESFARMA, SA (ES) | 2008-09-04 | — | — | US | disclosed |
| EP-1725552-B1 | NEW QUATERNIZED QUINUCLIDINE ESTERS | ALMIRALL LAB (ES) | 2008-06-25 | — | — | EP | disclosed |
| EP-1725552-A1 | NEW QUATERNIZED QUINUCLIDINE ESTERS | Almirall Prodesfarma, S.A. (ES) | 2006-11-29 | — | — | EP | disclosed |
| US-20060167042-A1 | antagonists of M3 muscarinic receptors; N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-hydroxy-2,2-dithien-2-ylacetamide; respiratory disorders, urological disorders, gastrointestinal disorders, cardiovascular disorders; alkylation | LABORATORIOS ALMIRALL S.A. (ES) | 2006-07-27 | — | — | US | disclosed |
| WO-2005090342-A1 | NEW QUATERNIZED QUINUCLIDINE ESTERS | ALMIRALL PRODESFARMA, SA (ES) | 2005-09-29 | — | — | WO | disclosed |
| EP-1519933-A1 | QUINUCLIDINE AMIDE DERIVATIVES | Almirall Prodesfarma AG (CH) | 2005-04-06 | — | — | EP | disclosed |
| WO-2004005285-A1 | NEW QUINUCLIDINE AMIDE DERIVATIVES | ALMIRALL PRODESFARMA AG (CH) | 2004-01-15 | — | — | WO | disclosed |
| WO-1989008830-A1 | THIOACYLATION PEPTIDE SEQUENCING WITH ALCOHOLYSIS OF THIAZOLINONES | BIO-AFFINITY SYSTEMS, INC. (US) | 1989-09-21 | — | — | WO | disclosed |
| US-4863870-A | Method of thioacylation peptide sequencing with alcoholysis of thiazolinones | BIO-AFFINITY SYSTEMS, INC. (US) | 1989-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214600-A1 | Quaternized Quinuclidine Esters | NQO2, QPCT, QARS1 | HPGD 165/4885ALOX5 1320/4885CES2 1023/4885 |
| US-20080234316-A1 | Quinuclidine Amide Derivatives | CHRM3, CHRM2, CHRM1 | HPGD 1612/4885ALOX5 4137/4885CES2 651/4885 |
| US-20060167042-A1 | antagonists of M3 muscarinic receptors; N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-hydroxy-2,2-dithien-2-ylacetamide; respiratory disorders, urological disorders, gastrointestinal disorders, cardiovascular disorders; alkylation | CHRM3, CHRM2, CHRM1 | HPGD 1353/4885ALOX5 2029/4885CES2 3208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.